PMID- 37532558
OWN - NLM
STAT- MEDLINE
DCOM- 20230804
LR  - 20230804
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 46
IP  - 8
DP  - 2023
TI  - Pharmacist-Urologist Collaborative Management for Patients with Renal Cell 
      Carcinoma Receiving Pazopanib Monotherapy.
PG  - 1065-1071
LID - 10.1248/bpb.b22-00917 [doi]
AB  - Pazopanib is one of recommended treatment for metastatic renal cell carcinoma 
      (RCC). Despite its effectiveness, patients often difficult to continue pazopanib 
      treatment due to adverse events (AEs). We established an ambulatory care pharmacy 
      practice that enables pharmacist-urologist collaboration to manage patients with 
      RCC. This study evaluated the usefulness of this collaborative management. We 
      retrospectively reviewed the medical records of 51 consecutive patients with 
      metastatic RCC receiving pazopanib at the Kobe City Medical Center General 
      Hospital between April 2014 and December 2020. Our collaborative management was 
      implemented in October 2016. The time to pazopanib discontinuation was compared 
      between patients who started pazopanib before (n = 30) and after (n = 21) the 
      implementation of the collaborative management. A multivariate Cox regression 
      analysis was performed to analyze the factors associated with pazopanib 
      discontinuation. In the collaborative management, the oncology pharmacists had a 
      total of 245 face-to-face patient consultations, and provided 286 suggestions 
      [according to supportive care in pazopanib treatment (214 suggestions) were most 
      frequent], and 236 (82.5%) were accepted by urologists. The median time to 
      discontinuation (6.1 months vs. 2.4 months, p = 0.024) was significantly longer 
      in the after group. Multivariate analysis showed that collaborative management 
      (hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.26-0.88, p = 0.017), and 
      Eastern Cooperative Oncology Group performance status (ECOG PS) >/=2 at pazopanib 
      initiation (HR 3.87, 95% CI 1.47-9.13, p = 0.008) were significantly associated 
      with pazopanib discontinuation. These results suggested that, compared to 
      conventional management, collaborative management is effective at prolonging the 
      time to pazopanib discontinuation.
FAU - Hirabatake, Masaki
AU  - Hirabatake M
AD  - Department of Pharmacy, Kobe City Medical Center General Hospital.
FAU - Ikesue, Hiroaki
AU  - Ikesue H
AD  - Department of Pharmacy, Kobe City Medical Center General Hospital.
FAU - Yoshino, Shintaro
AU  - Yoshino S
AD  - Department of Pharmacy, Kobe City Medical Center General Hospital.
FAU - Morimoto, Mayu
AU  - Morimoto M
AD  - Department of Pharmacy, Kobe City Medical Center General Hospital.
FAU - Yamasaki, Toshinari
AU  - Yamasaki T
AD  - Department of Urology, Kobe City Medical Center General Hospital.
FAU - Hashida, Tohru
AU  - Hashida T
AD  - Department of Pharmacy, Kobe City Medical Center General Hospital.
AD  - Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin 
      University.
FAU - Kawakita, Mutsushi
AU  - Kawakita M
AD  - Department of Urology, Kobe City Medical Center General Hospital.
FAU - Muroi, Nobuyuki
AU  - Muroi N
AD  - Department of Pharmacy, Kobe City Medical Center General Hospital.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 7RN5DR86CK (pazopanib)
RN  - 0 (Indazoles)
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Renal Cell/drug therapy/pathology
MH  - Pharmacists
MH  - Urologists
MH  - *Kidney Neoplasms/drug therapy/pathology
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Indazoles/therapeutic use
MH  - Angiogenesis Inhibitors/therapeutic use
OTO - NOTNLM
OT  - ambulatory care
OT  - collaborative management
OT  - pazopanib
OT  - pharmacist
OT  - renal cell carcinoma
EDAT- 2023/08/03 01:06
MHDA- 2023/08/04 06:43
CRDT- 2023/08/02 21:38
PHST- 2023/08/04 06:43 [medline]
PHST- 2023/08/03 01:06 [pubmed]
PHST- 2023/08/02 21:38 [entrez]
AID - 10.1248/bpb.b22-00917 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2023;46(8):1065-1071. doi: 10.1248/bpb.b22-00917.